This Pharma Stock Soared More Than 360% in November
Clovis Oncology benefited from a lot of good news last month.
Clovis Oncology
CLVS
CLVS
$12.86
-$0.57
-4.2%
BATS BZX Real Time Price as of December 13, 2019, 4:00 p.m. EST
View Interactive CLVS Charts
Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring developing and commercializing innovative anti-cancer agents in the United States Europe and additional international markets.
News & Analysis: Clovis Oncology
The Fool has written over 100 articles on Clovis Oncology.
Is Clovis Oncology Really a Buyout Candidate?
The stock price is soaring. Are investors getting ahead of themselves by speculating on a potential acquisition?
3 Top Growth Stocks to Buy in December
These three names could soar early in 2020.
The Return of M&A Activity Is Lifting These Biotech Stocks Today
A $9.7 billion deal and two failed takeover bids ushered in renewed enthusiasm for acquisitions in the pharmaceutical industry. What makes these stocks buyout candidates?
These 3 Value Stocks Are Absurdly Cheap Right Now
These dirt cheap healthcare stocks could be poised for a major upswing in 2020.
Clovis Oncology (CLVS) Q3 2019 Earnings Call Transcript
CLVS earnings call for the period ending September 30, 2019.
Will The Pace of M&A Pick Up Following The Biotech Sector’s Pounding?
With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
3 Cancer Treatment Stocks to Buy Right Now
These three beaten-down cancer stocks could prove to be amazing value plays.
Here's Why Clovis Oncology Fell as Much as 13.5% Today
Wall Street is questioning the value and purpose of a recent deal.
Near an All-Time Low, Is Clovis Oncology a Buy?
Investors need ongoing clinical trials to deliver -- and for the business to rein in expenses.
